This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 1, 2012
Last updated: December 10, 2012
Last verified: December 2012
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.

Condition Intervention Phase
Advanced Solid Tumors Drug: TAS266 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Frequency and characteristics of Dose limiting toxicities at each dose level [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Type, frequency, and severity of AEs, changes in laboratory and clinical assessments [ Time Frame: 2 years ]
  • TAS266 serum concentrations and PK parameters: Cmax, Tmax, AUC0-tlast, Tlast, T1/2 and accumulation ratio of TAS266 [ Time Frame: 8 timepoints each for Cycles 1 and 2, prior to dosing on Day 1 of Cycles 3, 4, 5 and 6, at End of Treatment ]
    1 Treatment Cycle = 28 days,) assuming maximum 6 cycles of treatment

  • Presence and concentration of anti-TAS266 antibodies [ Time Frame: 2 Years ]
  • Tumor response [ Time Frame: 2 Years ]

Enrollment: 6
Study Start Date: June 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAS266 Drug: TAS266
TAS266 IV infusions given weekly


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of solid tumors
  • 18 years or older
  • ECOG performance status of 0, 1 or 2
  • Adequate bone marrow, hepatic and renal function
  • Obtained written informed consent

Exclusion Criteria:

  • Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS metastases may be allowed if certain conditions are met.
  • Major surgery within 4 weeks before study treatment
  • Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations
  • Impaired cardiac functions
  • Previous hepatitis viral infection such as hepatitis B or hepatitis C
  • Diagnosis of HIV infection
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01529307

United States, Florida
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC
Tampa, Florida, United States, 33612
United States, Texas
South Texas Accelerated Research Therapeutics START
San Antonio, Texas, United States, 789229
United States, Utah
University of Utah / Huntsman Cancer Institute Huntsman UT
Salt Lake City, Utah, United States, 84103
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01529307     History of Changes
Other Study ID Numbers: CTAS266X2101
Study First Received: February 1, 2012
Last Updated: December 10, 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
solid tumors,
Death Receptor 5 agonist,
caspase-8 processed this record on August 22, 2017